Lunit said Lunit Scope PD-L1, its AI-powered pathology analysis solution, will be integrated into Roche Diagnostics' Navify Digital Pathology platform.

Navify enhances the efficiency of pathologists, offering a complete workflow that ranges from digitizing tissue slides to AI-based analysis.

According to Lunit, Roche Diagnostics aims to strengthen biomarker testing for cancer research and improve patient treatment outcomes through precision medicine based on this integration.

Lunit hopes to strengthen its position in the digital pathology market and provide AI-based solutions to a wider range of medical professionals and patients around the world.

The integration will initially be implemented in the U.S., with plans to expand to Europe, Korea, Japan, and other regions.

Lunit and Roche Diagnostics will also collaborate on product launches and marketing strategies, with Lunit focusing on AI algorithm development and enhancement, while Roche handles the integration and global sales.

"Roche Diagnostics' strategy of collaborating with various companies within the pathology ecosystem will create synergies that improve the quality of healthcare services," Lunit CEO Suh Beom-seok said. "By offering Lunit's accurate and reliable AI solution, we expect to advance precision medicine and personalized cancer treatment on a global scale."